Jones, Allison
https://orcid.org/0000-0002-9677-3950
Mayo Clinic
St. Jude Children's Research Hospital
Citations 2
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ansell, Stephen M. , Barnes, Jeffrey A. , Brammer, Jonathan E. , Clemens, Mark W. , Ghione, Paola , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shea, Lauren , Sokol, Lubomir , Wu, Peggy A. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, Hoppe, Richard T , Ghione, Paola , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Foss, Francine M. , Halwani, Ahmad , Kallam, Avyakta , Kim, Youn H , Kumar, Kiran Achut , Shinohara, Michi M. , Sokol, Lubomir , Torres‐Cabala, Carlos A. , Wilcox, Ryan A.
Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 285-308
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Halwani, Ahmad , Kim, Youn H , Sokol, Lubomir , Wilcox, Ryan A.
Journal of the National Comprehensive Cancer Network | November 5, 2020 | Volume: 18 | Issue: 11 | Pages: 1460-1467
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.